Dose | Group | Intimal hyperplasia | Subintimal fibrosis | Lymphocytic infiltration | Vascularity | Aggregate score |
---|---|---|---|---|---|---|
1D | HA | 2.45 ± 0.11 | 2.60 ± 0.11 | 1.50 ± 0.11a, b | 2.05 ± 0.11 | 7.80 ± 0.26a, b |
 | SA | 2.60 ± 0.11 | 2.60 ± 0.11 | 2.50 ± 0.11 | 2.10 ± 0.12 | 9.10 ± 0.31 |
 | No-tr | 2.65 ± 0.11 | 2.65 ± 0.10 | 2.95 ± 0.05 | 2.20 ± 0.12 | 9.75 ± 0.24 |
 | cP value among groups | P > 0.05 | P > 0.05 | P <0.001 | P > 0.05 | P <0.001 |
3D | HA | 2.50 ± 0.11 | 2.70 ± 0.11 | 1.40 ± 0.13a, b | 2.20 ± 0.09 | 8.05 ± 0.31a, b |
 | SA | 2.80 ± 0.09 | 2.70 ± 0.10 | 2.55 ± 0.11 | 2.15 ± 0.11 | 9.55 ± 0.28 |
 | No-tr | 2.80 ± 0.09 | 2.70 ± 0.11 | 2.85 ± 0.08 | 2.20 ± 0.14 | 9.95 ± 0.32 |
 | cP value among groups | P > 0.05 | P > 0.05 | P <0.001 | P > 0.05 | P <0.001 |
3D6d | HA | 2.50 ± 0.11 | 2.50 ± 0.11 | 1.40 ± 0.11a, b | 2.15 ± 0.11 | 7.85 ± 0.25a, b |
 | SA | 2.70 ± 0.11 | 2.60 ± 0.10 | 2.77 ± 0.10 | 2.20 ± 0.14 | 9.6 ± 0.36 |
 | No-tr | 2.70 ± 0.11 | 2.70 ± 0.11 | 2.85 ± 0.08 | 2.40 ± 0.11 | 10.05 ± 0.33 |